ABBV-CLS-484   Click here for help

GtoPdb Ligand ID: 11968

Synonyms: AC484
PDB Ligand
Compound class: Synthetic organic
Comment: ABBV-CLS-484 is an orally bioavailable, active-site inhibitor of the protein tyrosine phosphatases PTPN1/N2 that was developed by AbbVie, Calico Life Sciences, and the Broad Institute of MIT and Harvard. Its chemical structure was first disclosed at the AACR spring meeting in 2022, and subsequently published in a Nature Communications article in mid-2023 [2]. ABBV-CLS-484-mediated inhibition of PTPN1/N2 in T cells promotes a potent immune-dependent anti-tumour effect[1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 107.12
Molecular weight 385.15
XLogP 2.15
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(CCN[C@@H]1CCc2c(C1)c(F)c(c(c2)O)N1CC(=O)NS1(=O)=O)C
Isomeric SMILES CC(C)CCN[C@@H]1CCc2c(C1)c(F)c(N1CC(=O)NS1(=O)=O)c(O)c2
InChI InChI=1S/C17H24FN3O4S/c1-10(2)5-6-19-12-4-3-11-7-14(22)17(16(18)13(11)8-12)21-9-15(23)20-26(21,24)25/h7,10,12,19,22H,3-6,8-9H2,1-2H3,(H,20,23)/t12-/m1/s1
InChI Key DVFCRTGTEXUFIN-GFCCVEGCSA-N
No information available.
Summary of Clinical Use Click here for help
Initially the safety, PK and PD of ABBV-CLS-484 will be assessed in eligible patients with advanced solid tumours, and then its efficacy either as monotherapy or in combination with a PD-1 (checkpoint) inhibitor will be determined.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04777994 A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors Phase 1 Interventional Calico Life Sciences LLC